Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of EOM613 to treat patients with the most severe effects of COVID-19

X
Trial Profile

Effect of EOM613 to treat patients with the most severe effects of COVID-19

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 24 Dec 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AVR 118 (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Sponsors EOM Pharmaceuticals
  • Most Recent Events

    • 24 Dec 2020 New trial record
    • 23 Dec 2020 According to an EOM Pharmaceuticals media release, the company looks forward to finalizing the clinical study design and protocol for EOM613 with the advice and guidance of the FDA and to initiating our trial at a leading university medical center in the United States.
    • 23 Dec 2020 According to an EOM Pharmaceuticals media release, the company has filed a pre-Investigational New Drug Application (pre-IND) meeting request and complete pre-IND briefing documents with the U.S. Food and Drug Administration (FDA) to conduct this study.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top